If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma. Specifically it is used for open angle glaucoma when other agents are not sufficient. It may also be used to increase the size of the eyelashes. It is used as an eye drop and effects generally occur within four hours. Common side effects include red eyes, dry eyes, change in color of the eyes, blurry vision, and cataracts. Use during pregnancy or breastfeeding is generally not recommended. It is a prostaglandin analog and works by increasing the outflow of aqueous fluid from the eyes. Bimatoprost was approved for medical use in the United States in 2001. It is available as a generic medication. In 2023, it was the 238th most commonly prescribed medication in the United States, with more than 1 million prescriptions.
=== Names === Leuprorelin is the generic name of the drug and its INNTooltip International Nonproprietary Name and BANTooltip British Approved Name, while leuprorelin acetate is its BANMTooltip British Approved Name and JANTooltip Japanese Accepted Name, leuprolide acetate is its USANTooltip United States Adopted Name and USPTooltip United States Pharmacopeia, leuprorelina is its DCITTooltip Denominazione Comune Italiana, and leuproréline is its DCFTooltip Dénomination Commune Française. It is also known by its developmental code names A-43818, Abbott-43818, DC-2-269, and TAP-144. Leuprorelin is marketed by Bayer AG under the brand name Viadur, by Tolmar under the brand names Eligard and Fensolvi, and by TAP Pharmaceuticals (1985–2008), by Varian Pharmed( Previously named Varian Darou Pajooh) under the brand name Leupromer and Abbott Laboratories (2008–present) under the brand name Lupron.
Large portions of the book involve detailed discussions of mathematics, physics, and philosophy. Most of these discussions use fictional Arbran terminology, but treat ideas from actual science and philosophy. Stephenson acknowledges the work of author Julian Barbour as the source for much of this material. A major theme of the novel is the many-worlds interpretation of quantum mechanics based on a directed acyclic graph, which accounts for the various "worldtracks" and "narratives" explored by Fraa Orolo and manipulated by Fraa Jad. Another major theme is the recurring philosophical debate between characters espousing mathematical Platonic realism (called "Halikaarnians" in the novel and associated with Incanters) and characters espousing nominalism (called "Procians" in the novel and who are the Rhetors). Stephenson cites the work of Roger Penrose as a major influence on the novel. Specific ideas from Penrose's work include: the idea that the human mind operates in certain fundamental ways as a quantum computer, espoused in Penrose's The Emperor's New Mind; Platonic realism as a philosophical basis for works of fiction, as in stories from Penrose's The Road to Reality; and the theory of aperiodic tilings, which appear in the Teglon puzzle in the novel. Stephenson also cites as an influence the works of Kurt Gödel and Edmund Husserl, both of whom the character Durand mentions by name in the novel. Much of the Geometers' technology seen in the novel reflects existing scientific concepts. The alien ship moves by means of nuclear pulse propulsion.
self-organized convection in natural waters causing thermal cycling → added β-subunit of F1 ATP synthase (generated ATP by thermal cycling of subunit during suspension in convection cell: thermosynthesis) → added membrane and Fo ATP synthase moiety (generated ATP by change in electrical polarization of membrane during thermal cycling: thermosynthesis) → added metastable, light-induced electric dipoles in membrane (primitive photosynthesis) → added quinones and membrane-spanning light-induced electric dipoles (today's bacterial photosynthesis, which makes use of chemiosmosis).
Saline breast prosthesis filled with sterile saline solution. Silicone breast prosthesis filled with viscous silicone gel. Alternative-composition breast prosthesis filled with various fillers (soy oil, polypropylene string); now discontinued. Structured breast prosthesis constructed of nested shells, made of elastomer silicone, with saline solution filling the space between the silicone shells; now discontinued.
Sources: en.wikipedia.org
== Principles and training methods == Strength training follows the fundamental principle that involves repeatedly exercising a muscle group. This is typically done by contracting the muscles during an exercise and then returning to the starting position. This process may be repeated for several repetitions until the muscles reach the point of failure. Strength training typically follows the principle of progressive overload, in which muscles are subjected to gradually increasing resistance over time to stimulate adaptation and growth. They respond by growing larger and stronger. People who are beginning strength training are in the process of training the neurological aspects of strength, including the ability of the brain to generate a rate of neuronal action potentials that will produce a muscular contraction that is close to the maximum of the muscle's potential.
== Genomic location and tissue expression == The ABCC1 gene, the gene that encodes the ABCC1 protein, is found on chromosome 16 within the nucleus. The protein resides intracellularly on the basolateral side of the plasma membrane which differs from other ATP-binding cassette transporters that are found on the apical side of the membrane. While ABCC1 is generally found throughout most tissues in humans, it is particularly prevalent in the lungs, spleen, testes, kidneys, placenta, thyroid, bladder, and adrenal glands. It is also found in the endothelium cells of the blood-brain barrier.
Extrapyramidal signs Rhabdomyolysis, acute Ataxia Irregular heart beat Mild hypothyroidism Loss of milestones Delayed speech and language acquisition Delayed walking Abnormal liver enzymes Gastrointestinal dysmotility Generalised brain atrophy High blood ammonia levels Low blood sugar Involuntary muscle contractions Increased lactate in body Prolonged QT interval Seizure Occasional:
KN035 is the only PD-L1 antibody with subcutaneous formulation currently under clinical evaluations in the US, China, and Japan AUNP12 is a 29-mer peptide as the first peptic PD-1/PD-L1 inhibitor developed by Aurigene and Laboratoires Pierre Fabre that is being evaluated in clinical trial, following promising in vitro results. CA-170, discovered by Aurigene/Curis as the PD-L1 and VISTA antagonist, was indicted as a potent small molecule inhibitor in vitro. Thus, the compound is currently under phase I clinical trial over mesothelioma patients. BMS-986189 is a macrocyclic peptide discovered by Bristol-Myers Squibb of which the pharmacokinetics, safety and tolerability is currently being studied on healthy subjects. INCB086550 is a small-molecule PD-L1 inhibitor.
Maurer, Maurer, ed. (1983) [1961]. Air Force Combat Units of World War II (PDF) (reprint ed.). Washington, DC: Office of Air Force History. ISBN 0-912799-02-1. LCCN 61060979. Archived from the original (PDF) on 20 December 2016. Retrieved 17 December 2016. Maurer, Maurer, ed. (1982) [1969]. Combat Squadrons of the Air Force, World War II (PDF) (reprint ed.). Washington, DC: Office of Air Force History. ISBN 0-405-12194-6. LCCN 70605402. OCLC 72556. Archived from the original (PDF) on 20 December 2016. Retrieved 17 December 2016.
Sources: en.wikipedia.org
=== Territory === Bophuthatswana had a surface area of approximately 40,000 km2 (15,000 sq mi) and consisted of seven enclaves dispersed over the former South African provinces of Cape Province, Transvaal, and Orange Free State. Six of the enclaves were located relatively close together with three in the Cape Province and another three in Transvaal. The seventh enclave was in the Orange Free State between Bloemfontein and the Lesotho border. One of the enclaves shared a border with Botswana, while two of the enclaves were located near Pretoria and its surrounding industrial areas. The townships in these enclaves, such as Ga-Rankuwa and Mabopane continued to serve as dormitory townships for the supply of labour (as they had done prior to Bophuthatswana's independence) despite being located in Bophuthatswana territory. Other enclaves were similarly located near South African cities such as Rustenburg and Bloemfontein. The capital, Mmabatho, was situated in the enclave bordering Botswana. The territory and borders of the country were fluid as the South African government frequently incorporated territory into the country. As a result, when independence was declared in 1977, the country originally consisted of six enclaves but just before its reincorporation into South Africa, it had seven enclaves. Another example was the incorporation of Mafeking, which was located just outside the borders of Bophuthatswana when it gained independence in 1977, into the country in 1980 after a local referendum.
Nakamoto limited the block size to one megabyte. The limited block size and frequency can lead to delayed processing of transactions, increased fees and a bitcoin scalability problem. The Lightning Network, a second-layer routing network, is a potential scaling solution. Research shows a trend towards centralization in bitcoin as miners join pools for stable income. If a single miner or pool controls more than 50% of the hashing power, it would allow them to censor transactions and double-spend coins. In 2014, mining pool Ghash.io reached 51% mining power, causing safety concerns, but later voluntarily capped its power at 39.99% for the benefit of the whole network. A few entities also dominate other parts of the ecosystem such as the client software, online wallets, and simplified payment verification (SPV) clients.
==== Catalonia ==== The 2009–2011 Catalan independence referendums, a series of non-binding and unofficial referendums, "popular votes" (consultes populars), took place in municipalities around Catalonia. In them voters indicated whether they supported Catalan independence from Spain. The first such referendum took place in Arenys de Munt on 13 September 2009: there followed votes in Sant Jaume de Frontanyà on 12 December and in 166 other municipalities on 13 December. Another vote ensued in April 2011 in Barcelona. Provisional figures for the 13 December vote suggest a turnout of around 200,000 (30% of those eligible to vote). The 2012 Catalan independence demonstration was a protest march which occurred in central Barcelona in Catalonia, Spain, on 11 September 2012 during the National Day of Catalonia. Many newspapers and other news agencies described it as a "historic" demonstration and considered it to be the biggest protest march ever held in Catalonia since the restoration of democracy in Spain, surpassing other major demonstrations, including the 2010 Catalan autonomy protest. A non-binding Catalan self-determination referendum was held on Sunday, 9 November 2014, to gauge support on the political future of Catalonia. While also referred to as "Catalan independence referendum", the vote was rebranded as a "participation process" by the Government of Catalonia, after a "non-referendum popular consultation" on the same topic and for the same date had been suspended by the Constitutional Court of Spain.
Linear RGD peptides suffer from low binding affinity, rapid degradation by proteases, and lack of specificity for integrin type. RGD can be cyclized, or made into a cyclic compound, via disulfide, thioether, or rigid aromatic ring linkers. This leads to an increase in binding affinity and selectivity for integrin αVβ3 relative to αIIBβ3. For example, the cyclic peptide ACDCRGDCFCG, also known as RGD4C, was shown to be 200-fold more potent than commonly used linear RGD peptides. The structural rigidity of cyclic RGD peptides improves their binding properties and prevents degradation at the highly susceptible aspartic acid residue, thereby increasing their stability. Many RGD derivative drugs and diagnostics are cyclized, including Eptifibatide, Cilengitide, CEND-1, and 18F-Galacto-RGD, and 18F-Fluciclatide-RGD.
== Bibliography == Atwood, David A. (2013). Radionuclides in the Environment. John Wiley and Sons. ISBN 978-1-118-63269-7. Emsley, John (2011). Nature's Building Blocks: An A-Z Guide to the Elements. New York: Oxford University Press, USA. ISBN 978-0-199-60563-7. Hoffman, Klaus (2001). Otto Hahn: Achievement and Responsibility. Springer. Bibcode:2002ohar.book.....H. ISBN 978-0-387-95057-0. Lemire, Robert J. (2001). Chemical Thermodynamics of Neptunium and Plutonium. Amsterdam: Elsevier. ISBN 978-0-444-50379-4. Rhodes, Richard (2012). The Making of the Atomic Bomb (25th Anniversary ed.). New York: Simon & Schuster. ISBN 978-1-451-67761-4. Yoshida, Zenko; Johnson, Stephen G.; Kimura, Takaumi; Krsul, John R. (2006). "Neptunium". In Morss, Lester R.; Edelstein, Norman M.; Fuger, Jean (eds.). The Chemistry of the Actinide and Transactinide Elements (PDF). Vol. 3 (3rd ed.). Dordrecht, the Netherlands: Springer. pp. 699–812. doi:10.1007/1-4020-3598-5_6. ISBN 978-1-4020-3555-5. Archived from the original (PDF) on January 17, 2018.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.